{
  "docId": "019de070-5583-7544-b7b3-e17a9a5a1395",
  "docSlug": "6e951aba00c366c61ecceffedb425cf6",
  "documentTitle": "Alkermes | Results Presentation Deck | 12 slides",
  "authorId": "alkermes",
  "authorName": "Alkermes",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2020-10-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 5,
  "pageCount": 12,
  "prevPage": 4,
  "nextPage": 6,
  "slideType": "kpi_overview",
  "function": "analyze_data",
  "density": "balanced",
  "nDataPoints": 15,
  "notes": "The table highlights Q3'20 data with a green border.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de070-5583-7544-b7b3-e17a9a5a1395/5",
  "deckHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395",
  "deckJsonHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395.json",
  "deckAnchorHref": "/decks/019de070-5583-7544-b7b3-e17a9a5a1395#slide-5",
  "components": [
    {
      "bbox": {
        "h": 0.025,
        "w": 0.363,
        "x": 0.124,
        "y": 0.906
      },
      "kind": "disclaimer",
      "text": "Amounts in the table above do not sum due to rounding.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "40851785-887b-4199-a484-ad6e2c71d11f",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.025,
        "w": 0.736,
        "x": 0.124,
        "y": 0.868
      },
      "kind": "paragraph",
      "text": "* R&D revenues related to reimbursement for VUMERITY development expenses largely concluded in Q4'19 following FDA approval",
      "attrs": null,
      "subkind": "paragraph",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "9abfb325-3605-4d1a-a13c-9b5cf51cb1e7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.515,
        "w": 0.736,
        "x": 0.124,
        "y": 0.285
      },
      "kind": "table",
      "text": "VIVITROL $80.3 $85.2 (6%) ARISTADA $62.4 $53.6 16% Manufacturing & Royalty Revenue $120.4 $103.8 16% R&D and License Revenues $2.0 $12.7 (84%)* Total Revenue $265.0 $255.2 4%",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "1f78df91-788c-4fc5-bc8e-ef977980b5cf",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.048,
        "w": 0.435,
        "x": 0.036,
        "y": 0.105
      },
      "kind": "title",
      "text": "Third Quarter 2020 Revenue Summary",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "ffea40cc-aa79-49fa-80a6-bb000bfffe80",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "5df36312-27e8-45be-ab87-c9c052cad9ec",
      "evidence": "table/data: VIVITROL $80.3 $85.2 (6%) ARISTADA $62.4 $53.6 16% Manufacturing & Royalty Revenue $120.4 $103.8 16% R&D and License Revenues $2.0 $12.7 (84%)* Total Revenue $265.0 $255.2 4%",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [
    {
      "to": 5,
      "from": 4,
      "beatId": "21cdb74e-3d51-44fb-8882-45fa24264d0c",
      "arcName": "Monroe's Motivated Sequence",
      "arcSlug": "monroes-sequence",
      "beatName": "Need",
      "beatSlug": "monroes-sequence-need",
      "evidence": "The financial results summary slides highlight the need for update",
      "position": 1,
      "confidence": 0.8,
      "parentBeatName": "Complication",
      "parentBeatSlug": "complication"
    }
  ],
  "loops": [
    {
      "to": 5,
      "from": 4,
      "name": "Cost Of Inaction",
      "slug": "27-cost-of-inaction",
      "bestFor": "Urgent budget requests, compliance, risk mitigation",
      "matchId": "44f46f02-ec89-4521-b1c7-f4fd27afebee",
      "evidence": "The financial results summary slides imply the cost of inaction",
      "position": 0,
      "objective": "Highlighting the cost of inaction through financial results",
      "structure": "The Status Quo -> The Hidden Costs Accumulating -> The Future State of Inaction -> The Tipping Point",
      "confidence": 0.6,
      "description": "Quantify what happens if the audience does nothing"
    }
  ],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}